Literature DB >> 23993394

First trimester hyperglycosylated human chorionic gonadotrophin in serum - a marker of early-onset preeclampsia.

E Keikkala1, P Vuorela, H Laivuori, J Romppanen, S Heinonen, U-H Stenman.   

Abstract

INTRODUCTION: Recent studies indicate that treatment with low-dose aspirin may reduce the risk of preeclampsia. Thus, early prediction of preeclampsia is needed. Low serum concentrations of hyperglycosylated human chorionic gonadotrophin (hCG-h) are associated with early pregnancy loss. We therefore studied whether it may serve as an early marker of preeclampsia.
METHODS: A nested case-control study included 158 women with subsequent preeclampsia, 41 with gestational hypertension, 81 normotensive women giving birth to small-for-gestational-age (SGA) infants and 427 controls participating in first trimester screening for Down's syndrome between 8 and 13 weeks of gestation. Gestational-age-adjusted multiples of medians (MoMs) were calculated for serum concentrations of hCG-h, the free beta subunit of hCG (hCGβ) and pregnancy-associated plasma placental protein A (PAPP-A) and the proportion of hCG-h to hCG (%hCG-h). Clinical risk factors including mean arterial pressure (MAP) and parity were also included in the risk calculation.
RESULTS: In women with subsequent preeclampsia %hCG-h was lower than in controls (median MoM 0.92, P < 0.001), especially in 29 cases with early-onset preeclampsia (0.86, P < 0.001), in which PAPP-A also was reduced (0.95, P = 0.001). At 90% specificity for prediction of early-onset preeclampsia, sensitivity was 56% (95% confidence interval, 52-61%) for %hCG-h, 33% (28-37%) for PAPP-A, and 69% (51-83%) for the combination of these with first trimester MAP and parity. The area under the receiver-operating characteristic (ROC) curve for the combination of all these was 0.863 (0.791-0.935).
CONCLUSIONS: hCG-h is a promising first trimester marker for early-onset preeclampsia. Addition of PAPP-A and maternal risk factors may improve the results.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hyperglycosylated human chorionic gonadotrophin; Preeclampsia; Pregnancy-associated plasma protein A; Sensitivity and specificity; Small-for-gestational-age

Mesh:

Substances:

Year:  2013        PMID: 23993394     DOI: 10.1016/j.placenta.2013.08.006

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  13 in total

1.  Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Authors:  Nandor Gabor Than; Roberto Romero; Adi Laurentiu Tarca; Katalin Adrienna Kekesi; Yi Xu; Zhonghui Xu; Kata Juhasz; Gaurav Bhatti; Ron Joshua Leavitt; Zsolt Gelencser; Janos Palhalmi; Tzu Hung Chung; Balazs Andras Gyorffy; Laszlo Orosz; Amanda Demeter; Anett Szecsi; Eva Hunyadi-Gulyas; Zsuzsanna Darula; Attila Simor; Katalin Eder; Szilvia Szabo; Vanessa Topping; Haidy El-Azzamy; Christopher LaJeunesse; Andrea Balogh; Gabor Szalai; Susan Land; Olga Torok; Zhong Dong; Ilona Kovalszky; Andras Falus; Hamutal Meiri; Sorin Draghici; Sonia S Hassan; Tinnakorn Chaiworapongsa; Manuel Krispin; Martin Knöfler; Offer Erez; Graham J Burton; Chong Jai Kim; Gabor Juhasz; Zoltan Papp
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

2.  Combination of PAPPA, fhCGβ, AFP, PlGF, sTNFR1, and Maternal Characteristics in Prediction of Early-onset Preeclampsia.

Authors:  Anna Yliniemi; Kaarin Makikallio; Teemu Korpimaki; Heikki Kouru; Jaana Marttala; Markku Ryynanen
Journal:  Clin Med Insights Reprod Health       Date:  2015-06-11

Review 3.  Predictive factors for intrauterine growth restriction.

Authors:  A R Albu; A F Anca; V V Horhoianu; I A Horhoianu
Journal:  J Med Life       Date:  2014-06-25

4.  First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study.

Authors:  Elina Keikkala; Sini Koskinen; Piia Vuorela; Hannele Laivuori; Jarkko Romppanen; Seppo Heinonen; Ulf-Håkan Stenman
Journal:  BMC Pregnancy Childbirth       Date:  2016-11-25       Impact factor: 3.007

Review 5.  hCG: Biological Functions and Clinical Applications.

Authors:  Chinedu Nwabuobi; Sefa Arlier; Frederick Schatz; Ozlem Guzeloglu-Kayisli; Charles Joseph Lockwood; Umit Ali Kayisli
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

6.  Human chorionic gonadotropin (hCG) concentrations during the late first trimester are associated with fetal growth in a fetal sex-specific manner.

Authors:  Mirjana Barjaktarovic; Tim I M Korevaar; Vincent W V Jaddoe; Yolanda B de Rijke; Theo J Visser; Robin P Peeters; Eric A P Steegers
Journal:  Eur J Epidemiol       Date:  2016-10-05       Impact factor: 8.082

7.  Prediction of pre-eclampsia and its subtypes in high-risk cohort: hyperglycosylated human chorionic gonadotropin in multivariate models.

Authors:  Katja Murtoniemi; Pia M Villa; Jaakko Matomäki; Elina Keikkala; Piia Vuorela; Esa Hämäläinen; Eero Kajantie; Anu-Katriina Pesonen; Katri Räikkönen; Pekka Taipale; Ulf-Håkan Stenman; Hannele Laivuori
Journal:  BMC Pregnancy Childbirth       Date:  2018-07-03       Impact factor: 3.007

Review 8.  Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis.

Authors:  Yan Zhong; Fufan Zhu; Yiling Ding
Journal:  BMC Pregnancy Childbirth       Date:  2015-08-25       Impact factor: 3.007

9.  Evaluation of serum β-hCG and PAPP-A levels in pregnant women at risk of developing preeclampsia.

Authors:  Mihaela Daniela Oancea; Nicolae Costin; Daria Maria Pop; Razvan Ciortea; Dan Mihu
Journal:  Clujul Med       Date:  2013-11-06

10.  Platelet-derived factors impair placental chorionic gonadotropin beta-subunit synthesis.

Authors:  Désirée Forstner; Sabine Maninger; Olivia Nonn; Jacqueline Guettler; Gerit Moser; Gerd Leitinger; Elisabeth Pritz; Dirk Strunk; Katharina Schallmoser; Gunther Marsche; Akos Heinemann; Berthold Huppertz; Martin Gauster
Journal:  J Mol Med (Berl)       Date:  2019-12-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.